组织多肽特异性抗原检测在中晚期肿瘤治疗中的意义  

Monitoring of tissue polypeptide specific antigen in the treatment for advanced cancers and its significance

作　　者：沈晔华[1] 陈震[1] 宋明志[1] 

机构地区：[1]复旦大学附属肿瘤医院中医科,上海200032

出　　处：《中国癌症杂志》2003年第3期229-231,258,共4页China Oncology

摘　　要：目的 :研究组织多肽特异性抗原 (TPS)的检测在中晚期肿瘤治疗中的意义。方法 :检测 60例中晚期肿瘤患者的TPS。 42例接受肝介入治疗或化疗 ,对其中 30例消化系统肿瘤患者连续检测治疗前后的TPS。结果 :不同年龄、性别、疾病、分期的患者TPS浓度无显著性差异。初始TPS 30 0U/L以下的患者治疗有效率 (PR ,CR或MR)为 52 94% ;TPS超过 1 0 0 0U/L的患者无一例有效 ,55 56 %病情进展 (P <0 0 5)。随TPS变化的不同 ,患者的疗效呈现差别 ,与影像学的符合率为 63 33 %。结论Purpose:To determine the impact of serum tissue polypeptide specific antigen (TPS) in the treatment for advanced cancer patients. Methods:Serum TPS was examined in 60 advanced cancer cases. 42 of the patients received hepatic arterial chemoembolization or chemotherapy. For those with tumors derived from digestive system, TPS monitoring was performed in serial during the therapeutic courses. Results:No significant differentiation was observed in terms of age, gender, disease or tumor stage. Patients with initial TPS lower than 300 U/L had the most favorable response rate to treatment (PR,CR or MR) of 52.94%, while those with initial TPS higher than 1000 U/L showed no evidence of remission after therapy. 55.56% of the latter developed into PD ( P <0 05). Different responses to treatment also showed correlation to TPS changes, 63.33% of which were in accordance with the findings of images analysis. Conclusions:TPS Monitoring is valuable in treatment for patients with advanced malignant tumors. [

关 键 词：组织多肽特异性抗原 检测 中晚期 肿瘤 治疗 

分 类 号：R730.43[医药卫生—肿瘤]